AFMD250117C15000
- 0.75
- 0.000.00%
Affimed NV Newsroom
Leerink Partners Maintains Affimed NV(AFMD.US) With Buy Rating, Cuts Target Price to $5
H.C. Wainwright Maintains Affimed NV(AFMD.US) With Buy Rating, Maintains Target Price $7
Truist Financial Maintains Affimed NV(AFMD.US) With Buy Rating
H.C. Wainwright Maintains Affimed NV(AFMD.US) With Buy Rating, Cuts Target Price to $7
Express News | Affimed NV : H.c. Wainwright Cuts Target Price to $7 From $10
Wells Fargo Maintains Affimed NV(AFMD.US) With Buy Rating, Cuts Target Price to $11
Express News | Affimed Shares Are Trading Lower. The Company Reported Findings From a Post-hoc Exposure-response Analysis in Patients Treated With 480 Mg AFM24
Affimed Reports Results for Cancer Therapy in NSCLC Patients
Affimed Is Maintained at Overweight by Wells Fargo
Wells Fargo Maintains Affimed NV(AFMD.US) With Buy Rating, Cuts Target Price to $15
Affimed Reports Efficacy, Safety Data From Leukemia Treatment Study
Affimed Reports Phase 1 Efficacy And Safety Data For AFM28 In Relapsed/Refractory Acute Myeloid Leukemia; AFM28, A Bispecific, Tetravalent Innate Cell Engager Targeting CD123 And CD16A, Achieved A 40% Composite Complete Remission Rate At The Highest...
Affimed to Review Clinical Data From Lung Cancer Trial on December 17
Biggest Stock Movers Monday: SMCI, MOMO, and More
Affimed Announced at ASH Meeting, Combination Of Acimtamig With AlloNK Demonstrated An Overall Response Rate Of 86%
Express News | The FDA Has Granted RMAT Designation To The Combination Therapy Of Affimed's Acimtamig And Artiva Biotherapeutic's AlloNK (AB101) For Relapsed Or Refractory Hodgkin Lymphoma
Is Affimed N.V. (AFMD) the Best German Stock to Buy Now?
Express News | Cantor Fitzgerald Reiterates Overweight on Affimed
Stifel Maintains Affimed NV(AFMD.US) With Hold Rating, Cuts Target Price to $4
Affimed Is Maintained at Hold by Stifel